JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
15/12/23 - 17:38
Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
03/11/23 - 15:51
Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
27/07/23 - 13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
09/05/23 - 11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
27/03/23 - 14:38
Dividend coupon date correction (493.46 KB)
27/03/23 - 13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
09/11/17 - 14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
29/09/17 - 15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
03/08/17 - 14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
26/06/17 - 9:45
DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
08/05/17 - 19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
27/04/17 - 18:45
DiaSorin - Annual General Meeting 2016 (421.04 KB)
08/03/17 - 15:30